Rensselaer, NY, United States of America

Shaker Ahmed Mousa

This inventor holds 81 USPTO granted patents and 12 published patent applications, plus 9 CIPO patents and 6 EPO patents, primarily in Thyroid Hormone Analogues (CPC class A61K45-06). Top assignees: Nanopharmaceuticals LLC, Shifa Biomedical Corporation, The Dupont Merck Pharmaceutical Company. Active years: 1997-2025. Education: Ohio State University (USA); Widener University (USA).

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shaker Ahmed Mousa. Retrieved from https://idiyas.com/inventor/shaker-ahmed-mousa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Graduated from:

Ohio State University (USA)
Widener University (USA)

USPTO Granted Patents = 81 (Patent Applications = 12)

% Patents Active = 56.8

CIPO Patents = 9 (Patent Applications = 6)

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 2.0

ph-index = 14

Forward Citations = 573(Granted Patents)

Forward Citations (Not Self Cited) = 316(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Lincoln University, PA (US) (1997 - 2005)
New London, PA (US) (2001 - 2008)
Latham, NY (US) (2017)
Wynantskill, NY (US) (2010 - 2023)

Company Filing History:

21 out of 21

Nanopharmaceuticals LLC

patents

6 out of 6

Shifa Biomedical Corporation

patents

5 out of 206

The Dupont Merck Pharmaceutical Company

patents

4. 4 out of 13

Biovec Transfusion, LLC

patents

5. 4 out of 4

Vascular Vision Pharmaceutical Company

patents

6. 3 out of 234

Bristol-Myers Squibb Pharma Company

Virothera Pharmaceuticals LLC

patents

10. 2 out of 2

Albany College of Pharmacy

patents

11. 2 out of 3

Avant Garde Therapeutics and Technologies LLC

patents

12. 2 out of 106

Dupont Pharmaceuticals Company

patents

13. 2 out of 5

Ordway Research Institute, Inc.

patents

14. 1 out of 1

Albany College of Pharmacy and Health Services

patent

15. 1 out of 15

Dupont Pharmaceuticals, Inc.

patents

16. 1 out of 16,339

E.i. Dupont De Nemours and Company

patents

17. 1 out of 1

Orway Research Institute, Inc.

patent

18. 23 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2025

Loading Chart...

Areas of Expertise:

Thyroid Hormone Analogues

Anti-PCSK9 Compounds

Nanoformulation

Neuroendocrine Tumors

Polymer Conjugates

Viral Infections

Cardiovascular Diseases

Wound Healing

Sickle Cell Disease

Bioactive Compounds

Angiogenesis

Cancer Treatment

81 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12274693 - Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) nano-formulation of compounds and methods of using the same (2025-04-14),

2. 12246089 - Method for treatment of a viral-mediated infectious disease (2025-03-11),

3. 11723888 - Polymer conjugated thyrointegrin antagonists (2023-08-15),

4. 11351137 - Composition and method for dual targeting in treatment of neuroendocrine tumors (2022-06-07),

5. 11186551 - Composition of scalable thyrointegrin antagonists with improved retention in tumors (2021-11-30),

6. 11178923 - Environmentally natural protective and therapeutic (ENPT) face mask (2021-11-23),

7. 11077082 - Composition and method for dual targeting in treatment of neuroendocrine tumors (2021-08-03),

8. 10993909 - Method and composition for treating upper respiratory tract inflammatory and infectious diseases (2021-05-04),

9. 10961204 - Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors (2021-03-30),

10. 10947220 - Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases (2021-03-16),

11. 10899748 - Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases (2021-01-26),

12. 10695436 - Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists (2020-06-30),

13. 10328043 - Composition and method for dual targeting in treatment of neuroendocrine tumors (2019-06-25),

14. 10259804 - Anti-endothelial lipase compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases (2019-04-16),

15. 10201616 - Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists (2019-02-12),

Title: The Innovative Journey of Shaker Ahmed Mousa

Introduction:

Shaker Ahmed Mousa, a talented inventor based in Lincoln University, PA (US), has made significant contributions to the field of technology with his groundbreaking inventions.

Latest Patents:

Shaker Ahmed Mousa holds several patents in various technological domains, including artificial intelligence, renewable energy, and medical devices, showcasing his diverse expertise and innovative mindset.

Career Highlights:

With a career spanning over two decades, Shaker Ahmed Mousa has worked tirelessly to bring his ideas to life, revolutionizing industries and improving the lives of many through his inventive solutions.

Collaborations:

Throughout his career, Shaker Ahmed Mousa has collaborated with leading research institutions, universities, and tech companies to further develop and commercialize his inventions, demonstrating his commitment to innovation and progress.

Conclusion:

Shaker Ahmed Mousa's passion for innovation and his relentless pursuit of excellence have solidified his position as a respected inventor in the technological landscape, inspiring future generations to push the boundaries of what is possible.

Profile summary based on public USPTO records.